24/7 Market News Snapshot 08 January, 2025 – Sensei Biotherapeutics, Inc. Common Stock (NASDAQ:SNSE)

January 8, 2025

DENVER, Colo., 08 January, 2025 (247marketnews.com) – (Nasdaq:SNSE) are discussed in this article.
Sensei Biotherapeutics, Inc. (Nasdaq:SNSE) is experiencing a notable uptick in its stock performance, trading at $0.571—an increase of approximately 10.44% from the previous close of $0.517. This surge is accompanied by a significant trading volume of 7.25 million shares, indicative of increased investor interest and activity. Technical indicators suggest a positive market sentiment, possibly spurred by promising developments surrounding the company’s clinical advancements.

The biotechnology firm is making strides in the development of its lead product candidate, solnerstotug (SNS-101), a next-generation therapy targeting the immune checkpoint VISTA. The company aims to fully enroll the dose expansion arm of its Phase 1/2 clinical trial by the end of the first quarter of 2025, with clinical data updates anticipated in the following quarter. John Celebi, President and CEO, highlighted the progress made over the past year, emphasizing the drug’s potential to address safety and efficacy challenges often faced by first-generation antibodies in targeting VISTA.

Solnerstotug selectively targets the VISTA checkpoint within the tumor microenvironment, aligning with data that reveals a correlation between VISTA expression and poor survival rates across various cancer types. The ongoing multi-center trial is evaluating the drug as a standalone treatment and in combination with Regeneron’s PD-1 inhibitor, Libtayo® (cemiplimab), for patients with advanced solid tumors.

Currently, Sensei has enrolled 45 patients in the dose expansion cohort, aiming for a total of approximately 60 by the end of March 2025. Many of these individuals have previously seen disease progression on anti-PD-1 therapies, highlighting the need for innovative treatment options. With cash runway projections extending into the second quarter of 2026, Sensei is poised for continued advancements in the development of solnerstotug, focusing on optimizing dosages and identifying relevant biomarkers.

Related news for (SNSE)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.